SRR598671
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.467
- ALLOGRAFT_REJECTION+0.405
- KRAS_SIGNALING_DN+0.374
- INTERFERON_ALPHA_RESPONSE+0.370
- IL6_JAK_STAT3_SIGNALING+0.369
- INTERFERON_GAMMA_RESPONSE+0.338
- KRAS_SIGNALING_UP+0.332
- COMPLEMENT+0.327
- APICAL_SURFACE+0.321
- IL2_STAT5_SIGNALING+0.256
Top 10 suppressed
- MYC_TARGETS_V2-0.612
- OXIDATIVE_PHOSPHORYLATION-0.600
- DNA_REPAIR-0.566
- MYC_TARGETS_V1-0.523
- UNFOLDED_PROTEIN_RESPONSE-0.514
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.464
- E2F_TARGETS-0.405
- MTORC1_SIGNALING-0.371
- G2M_CHECKPOINT-0.353
- UV_RESPONSE_UP-0.321
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607478 | GTEX | — | 0.944 |
| 2 | SRR1500800 | GTEX | — | 0.933 |
| 3 | SRR817758 | GTEX | — | 0.933 |
| 4 | SRR1394297 | GTEX | — | 0.932 |
| 5 | SRR1500639 | GTEX | — | 0.929 |
| 6 | SRR1331289 | GTEX | — | 0.927 |
| 7 | SRR821690 | GTEX | — | 0.919 |
| 8 | SRR1489971 | GTEX | — | 0.917 |
| 9 | SRR1320012 | GTEX | — | 0.916 |
| 10 | SRR598894 | GTEX | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.467 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.405 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.374 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.369 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.338 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.332 | Inavolisib | — uncovered |
| COMPLEMENT | 0.327 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.321 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.256 | Idelalisib | — uncovered |
| COAGULATION | 0.239 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.238 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.225 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.161 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.144 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.133 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.124 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.111 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.108 | Inavolisib | — uncovered |